TherapeuticsMD, Inc. — Director's Dealing 2022

Mar 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2022-03-23

Reporting Person: Glickman Mark A (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-23	Restricted Stock Units	$0.00	A	260000	Acquired		Common Stock (260000)	Direct

Footnotes

F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025.